Skip to primary content
Skip to secondary content

Biotech 365

Main menu

  • Biotech 365
  • Companies
  • Healthcare Investors
    • Healthcare LPs
  • Healthcare Investors Matchmaking
  • Free DEMO
  • Services
    • Preclinical Studies Database
    • Scientific Due Diligence
    • CRO & CDMO Database
  • Contact

Tag Archives: B-select antibody

Aduro Biotech – engineered Immunotherapy for Cancer

Posted on by

Aduro Biotech is a clinical-stage cancer immunotherapy company with multiple therapeutic approaches in development that have the potential to yield powerful immunotherapy combinations.

Aduro Biotech – engineered Immunotherapy for Cancer

Aduro Biotech

Continue reading →

Posted in Biotech Companies, Biotech Companies America, Biotech Companies Clinical Stage, Biotech Companies Diabetes, Biotech Companies Drug Development, Biotech Companies Metabolism, Biotech Companies Monoclonal Antibodies mAbs, Biotech Companies Oncology Cancer, Biotech Companies Pancreatic Cancer, Biotech Companies Therapeutics, Biotech Companies USA | Tagged Aduro, Aduro Biotech, Aduro Biotech - engineered Immunotherapy for Cancer, B-select, B-select antibodies, B-select antibody, cancer immunotherapy, CDN, CDNs, CRS-207, cyclic dinucleotide, cyclic dinucleotides, engineered Immunotherapy Cancer, engineered Immunotherapy for Cancer, GVAX Pancreas, LADD, live attenuated double-deleted Listeria mononcytogenes, metastatic pancreatic cancer

        Services              Healthcare Investors Database              FAQs               CGU               Biotech & Pharma News             Contact
Proudly powered by WordPress